Dr. Robert Salata, Case Western
Convalescent Plasma - not been highly effective
so monoclonal antibodies signaled to be better /2
Convalescent Plasma - not been highly effective
so monoclonal antibodies signaled to be better /2
#Regeneron abandoned use in Hospitalized patients
#NIH pivot HIV trials in monoclonal antibody
target ambulatory patients, not using oxygen /3
#NIH pivot HIV trials in monoclonal antibody
target ambulatory patients, not using oxygen /3
1.6% of those receiving antibodies needed hospitalization, big improvement over placebo control
creating more outpatient infusion centers /4
creating more outpatient infusion centers /4
targeting their own health care workers and vulnerable populations (all foregoing about Eli Lilly trial) /5
re #Regereron antibody cocktail... #clinicaltrial on mild/moderate (two-arm) within three days of a positive test. 3% vs 8% (placebo) needed hospitalization /6
EUA targeted high risk, BMI >35, diabetes, kidney disease, immuno-compromised, 65+ or 55+ with CVD, COPD, hypertension /7
only 500 monoclonal antibody dose available in Case Western Reserve system
some allergic reactions and other side effects, so infusion sites requires medical observation /8
some allergic reactions and other side effects, so infusion sites requires medical observation /8
some states set up lottery systems for treatment. Need more data, larger populations trialed /9
only recommended for children over 12 /10
• • •
Missing some Tweet in this thread? You can try to
force a refresh
